Изучение перспектив использования антигена NS4А вируса гепатита С для разработки мозаичной рекомбинантной вакцины с самоадъювантными свойствами
https://doi.org/10.31631/2073-3046-2017-16-1-69-74
Аннотация
Об авторах
В. В. КуприяновРоссия
Л. И. Николаева
Россия
А. А. Зыкова
Россия
П. И. Махновский
Россия
Список литературы
1. Wendt A., Adhoute X., Castellani P., Ansaldi C., Benali S. et. al. Chronic hepatitis C: future treatment. Clin. Pharmacol. 2014; 6: 1 - 17.
2. Gower E., Estes C., Blach S., Razavi-Shearer K., Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatology. 2014; 61: S45 - S57.
3. World Health Organization. Fact sheet. July 2016.
4. Mohd Hanafian K., Groeger J., Flexman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57: 1333 - 1342.
5. Terrault N., Monto A., Stinchon M.R., Rusie E., Moreo K. New therapies, evidence, and guidance in hepatitis C management: expert practices and insights from an educational symposium at the AMCP 27th Annual Meeting Expo. J. Manag. Care Spec. Pharm. J. Manag. Care Spec. Pharm. 2015; 21: S1 - 14.
6. Choo Q.-L., Kuo G., Weiner A.L., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone from blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244: 359 - 362.
7. Choo Q.-L., Kuo G., Ralson R., Weiner A., Chien D., Van Nest G. et al. Vaccination of chimpanzees against infection by hepatitis C virus. PNAS USA. 1994; 88: 2451 - 2455.
8. Catanese M.T., Uryu K., Kopp M., Edwards T.J., Andrus L., Rice W.J. et al. Ultrastructural analysis of hepatitis C virus particles. PNAS USA. 2013; 110: 9505 -9510.
9. Ray R., Meyer K., Banerjee A., Basu A., Coates St., Abrignani S. et.al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J. Infect. Dis. 2010; 202: 862 - 6.
10. Meyer K., Banerjee A., Frey Sh.E., Belshe R.B., Ray R. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. PLoS One. 2011, 6: e23699.
11. Folgoni A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole B.B. et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 2006; 12: 190 - 197.
12. Klade C.S., Wedemeyer H., Berg T., Hinrichsen H., Cholewinska G., Zeuzem S. et.al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterol. 2008; 134: 1385 - 1395.
13. Биоинформационный сайт: www.bioinformation.net
14. Kangueane P., Sakharkar M.K. T-epitope designer: a HLA-peptide binding prediction server. Bioinformation. 2005; 1: 21 - 24.
15. Singh H., Raghava G.P.S. ProPre 1: prediction of promiscuous MHC class-1 binding sites. Bioinformation. 2003; 19: 1009 - 14.
16. Li X.D., Sun L., Seth R.B., Pineda G., Chen Z.J. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. PNAS USA. 2005; 102: 17717 - 17722.
17. Desombere L., Van Vlierberghe H., Wieland O., Hultgren C., Sallberg M., Quiroga J. et al. Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. J. Med. Virol. 2007; 79: 701 - 713.
18. Nikolaeva L.I., Makashova V.V., Petrova E.V., Shipulin G.A., Samokhvalov E.I., Tokmalaev A.K. et al. The decline in antibodies to hepatitis C virus during antiviral therapy. Biochemistry (Moscow) Series B: Biomedical chemistry. 2009; 3: 202 - 209.
19. Chang J.C., Seidel C., Ofenloch B., Jue D.L., Fieds H.A., Khudyakov Y.E. Antigenic heterogeneity of the hepatitis C virus NS4 protein as modeled with synthetic peptides. Virology. 1999; 257: 177 - 190.
20. Berm dez-Aguirre A.D., Padilla-Noriega I., Zenteno E., Reyes-Leyva J. Identification of amino acid variants in the hepatitis C virus non-structural protein 4A. Tohoku J. Exp. Med. 2009; 218: 165 - 175.
21. Faulkner L., Buchan G., Lockhart E., Slobbe L., Wilson M., Baird M. IL-2 linked to a peptide from influenze hemagglutinin enhances T cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells. Int. Immunol. 2001; 13: 713 - 721.
22. Wolf A.I., Mozdzanowska K., Williams K.L., Singer D., Richter M., Hoffmann et. al. Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice. PLoS One. 2011; 6: e28445.
23. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nature Rev. Immunol. 2010; 10: 787 - 796.
24. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C. et. al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. PNAS USA, 2002; 99: 15661 - 15668.
25. Thimme R., Lohmann V., Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Research. 2006; 69: 129 - 1241.
26. Lancaster T., Sanders E., Christie M.L., Brooks C., Green S., Rosenberg M.C. Quantitative and functional differences in CD8+T-lymphocyte responses in resolved acute and chronic hepatitis C virus infection. J. Viral. Hepatitis. 2002; 9: 18 - 28.
27. Boettler T., Spangenberg H.C., Neurmann-Haefelin C., Panther E., Urbani S., Ferrari C. et.al. T cells with a CD4+CD25+regulatory phenotype suppress in vitro proliferation of virus-specific CD8+T cells during chronic hepatitis C virus infection. 2005; 79: 7860 - 7867.
28. Semmo N., Klenerman P. CD4+ T cell responses in hepatitis C virus infection. World J. Gastroenterol. 2007; 13: 4831 - 4838.
29. Lan R.Y., Selmi C., Gershwin M.E. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J. Autoimmun. 2008; 31: 7 - 12.
Рецензия
Для цитирования:
Куприянов В.В., Николаева Л.И., Зыкова А.А., Махновский П.И. Изучение перспектив использования антигена NS4А вируса гепатита С для разработки мозаичной рекомбинантной вакцины с самоадъювантными свойствами. Эпидемиология и Вакцинопрофилактика. 2017;16(1):69-74. https://doi.org/10.31631/2073-3046-2017-16-1-69-74
For citation:
Koupriyanov V.V., Nikolaeva L.I., Zykova A.A., Makhnovskiy P.I. The Investigation of the Prospects for Using NS4A Antigen of Hepatitis C Virus for the Development of Recombinant Mosaic Vaccines with Self-Adjuvant Properties. Epidemiology and Vaccinal Prevention. 2017;16(1):69-74. (In Russ.) https://doi.org/10.31631/2073-3046-2017-16-1-69-74